1-7 of 7
Andrew X. Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment

Bo Hu, Mincheng Yu, Xiaolu Ma, Jialei Sun, Chenglong Liu, Chunyan Wang, Suiyi Wu, Peiyao Fu, Zhen Yang, Yungang He, Yuanyuan Zhu, Cheng Huang, Xinrong Yang, Yinghong Shi, Shuangjian Qiu, Huichuan Sun, Andrew X. Zhu, Jian Zhou, Yang Xu, Di Zhu, Jia Fan
Journal: Cancer Discovery
Cancer Discov (2022) 12 (7): 1718–1741.
https://doi.org/10.1158/2159-8290.CD-21-1022
Published: 06 July 2022
View article titled, IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment
Open the PDF for IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment in another window
Includes: Supplementary data
Journal Articles

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Qibiao Wu, Yuanli Zhen, Lei Shi, Phuong Vu, Patricia Greninger, Ramzi Adil, Joshua Merritt, Regina Egan, Meng-Ju Wu, Xunqin Yin, Cristina R. Ferrone, Vikram Deshpande, Islam Baiev, Christopher J. Pinto, Daniel E. McLoughlin, Charlotte S. Walmsley, James R. Stone, John D. Gordan, Andrew X. Zhu, Dejan Juric, Lipika Goyal, Cyril H. Benes, Nabeel Bardeesy
Journal: Cancer Discovery
Cancer Discov (2022) 12 (5): 1378–1395.
https://doi.org/10.1158/2159-8290.CD-21-1168
Published: 02 May 2022
View article titled, EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
Open the PDF for EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong-Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung-Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia-Jui Yen, Jean-Francois Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt-Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon-Koo Kang
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (12): 1696–1707.
https://doi.org/10.1158/2159-8290.CD-19-0555
Published: 02 December 2019
View article titled, First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Open the PDF for First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

Lipika Goyal, Lei Shi, Leah Y. Liu, Ferran Fece de la Cruz, Jochen K. Lennerz, Srivatsan Raghavan, Ignaty Leschiner, Liudmila Elagina, Giulia Siravegna, Raymond W.S. Ng, Phuong Vu, Krushna C. Patra, Supriya K. Saha, Raul N. Uppot, Ron Arellano, Stephanie Reyes, Takeshi Sagara, Sachie Otsuki, Brandon Nadres, Heather A. Shahzade, Ipsita Dey-Guha, Isobel J. Fetter, Islam Baiev, Emily E. Van Seventer, Janet E. Murphy, Cristina R. Ferrone, Kenneth K. Tanabe, Vikram Deshpande, James J. Harding, Rona Yaeger, Robin K. Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (8): 1064–1079.
https://doi.org/10.1158/2159-8290.CD-19-0182
Published: 01 August 2019
View article titled, TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Open the PDF for TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

New Horizons for Precision Medicine in Biliary Tract Cancers

Juan W. Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X. Zhu
Journal: Cancer Discovery
Cancer Discov (2017) 7 (9): 943–962.
https://doi.org/10.1158/2159-8290.CD-17-0245
Published: 31 August 2017
View article titled, New Horizons for Precision Medicine in Biliary Tract Cancers
Open the PDF for New Horizons for Precision Medicine in Biliary Tract Cancers in another window
Journal Articles

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura Henderson, Jiaoyuan Elisabeth Sun, Emily E. Van Seventer, Joseph M. Gurski, Jr, Sabrina Baltschukat, Barbara Schacher-Engstler, Louise Barys, Christelle Stamm, Pascal Furet, David P. Ryan, James R. Stone, A. John Iafrate, Gad Getz, Diana Graus Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy, Andrew X. Zhu
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (3): 252–263.
https://doi.org/10.1158/2159-8290.CD-16-1000
Published: 05 March 2017
View article titled, Polyclonal Secondary <em>FGFR2</em> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Open the PDF for Polyclonal Secondary <em>FGFR2</em> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma

Supriya K. Saha, John D. Gordan, Benjamin P. Kleinstiver, Phuong Vu, Mortada S. Najem, Jia-Chi Yeo, Lei Shi, Yasutaka Kato, Rebecca S. Levin, James T. Webber, Leah J. Damon, Regina K. Egan, Patricia Greninger, Ultan McDermott, Mathew J. Garnett, Roger L. Jenkins, Kimberly M. Rieger-Christ, Travis B. Sullivan, Aram F. Hezel, Andrew S. Liss, Yusuke Mizukami, Lipika Goyal, Cristina R. Ferrone, Andrew X. Zhu, J. Keith Joung, Kevan M. Shokat, Cyril H. Benes, Nabeel Bardeesy
Journal: Cancer Discovery
Cancer Discov (2016) 6 (7): 727–739.
https://doi.org/10.1158/2159-8290.CD-15-1442
Published: 30 June 2016
View article titled, Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Open the PDF for Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data